Understand testosterone results through symptoms, repeat morning tests, laboratory methods, reference ranges, SHBG and free testosterone.
How do you read a testosterone test without overreading the number? Interpret it alongside relevant symptoms and signs, repeat fasting morning measurements and the reliability of the laboratory method.
This article is for informational purposes and is not medical advice. A qualified clinician should make individual decisions about testing, diagnosis and treatment.
Not by itself. The European Association of Urology (EAU) describes late-onset hypogonadism as a clinical diagnosis that combines compatible symptoms or signs with consistently low morning total testosterone. Reliable measurement and fasting conditions are part of that framework.
The number matters, but so does the reason for measuring it. A result obtained because of reduced libido raises a different clinical question from a result found during an assessment of general tiredness.
The useful distinction is between a finding and an explanation. A low measurement is a finding that deserves interpretation. Deciding whether it explains a man's symptoms requires the rest of the clinical assessment.
For someone facing an unexpected result, the appropriate next step is qualified review rather than a treatment decision based on the report alone. The clinician needs to understand both the concern that prompted testing and the circumstances behind the measurement.
According to the EAU's symptom table, some sexual symptoms are more specific to hypogonadism than general complaints. These include:
The guideline places fatigue and low energy among less-specific symptoms. Reduced strength, sleep disturbance and concentration difficulties also fall into that group.
Less specific does not mean unimportant. It means the symptom provides less support for a testosterone explanation by itself. These concerns still deserve assessment even when their cause is uncertain.
Even the more specific symptoms are not exclusive to hypogonadism. The EAU also cautions that symptom questionnaires have poor specificity for systematic screening. Counting matching items is therefore not a reliable substitute for assessment.
For a clinical discussion, it is useful to describe the symptoms that prompted testing rather than presenting a self-assigned hormone diagnosis. Testostra's guide to putting biomarkers beside symptoms provides context for that conversation.
The EAU recommends testosterone testing between 07:00 and 10:00, in fasting conditions. Its diagnostic framework requires consistently low morning total testosterone on at least two occasions before treatment is considered.
These conditions matter because measurements obtained under different circumstances are not necessarily equivalent. The EAU guideline cites evidence that non-fasting testing may underestimate total testosterone by more than 30%. That is a possible effect rather than something that happens to every person.
The practical implication is to review collection conditions with a clinician, rather than adding a percentage to the reported number. The reported result needs confirmation under appropriate conditions rather than a homemade correction.
Repeat measurement addresses whether the low finding is consistent. It is not simply an administrative step between an initial result and treatment.
Useful information to bring to the discussion includes the collection time and whether the sample was fasting. Relevant illness and medications also belong in the review. When several reports are involved, comparing them without assuming every difference is meaningful helps keep attention on the testing conditions as well as the values.
The EAU uses 12 nmol/L (3.5 ng/mL) as a threshold for late-onset hypogonadism, interpreted alongside symptoms and the wider clinical picture rather than as an automatic treatment trigger.
A laboratory's reference interval also needs context. It should not be assumed to be interchangeable with an interval printed by another laboratory. The EAU highlights differences in laboratory practices and procedures before a sample is analyzed.
The guideline notes that commercial immunoassay reference data may not clearly specify the reference population or the conditions under which samples were collected. A range printed on a report therefore deserves attention alongside the result itself.
For a clinician conversation, useful questions include which reference interval applies and how it relates to the clinical threshold being used. The goal is not to choose whichever range makes a result look reassuring or concerning. It is to understand the basis for interpretation.
Our article on reading a reference interval in clinical context develops that distinction further.
The EAU identifies LC-MS/MS as the most accurate method for sex-steroid evaluation. It also states that standardized automated immunoassays for total testosterone correlate well with LC-MS/MS. An immunoassay label alone is therefore not a reason to dismiss a total testosterone result.
The broader issue is comparability. The guideline notes variation in laboratory practices and procedures before analysis. It emphasizes reliable measurement and standardization so results can be interpreted accurately across laboratories.
When reviewing reports from different laboratories, useful questions include:
A difference between reports should be assessed with those questions in mind before being treated as a change in hormone status. The values are part of the comparison, but the measurement process also belongs in it.
This is a reason to seek clarification about a report, not a reason to assume laboratory testing is unreliable. The EAU's guidance supports attention to method quality rather than blanket rejection of one testing approach.
The EAU uses total testosterone in its diagnostic framework. It recommends considering SHBG measurement and free-testosterone calculation when a condition may alter SHBG or when additional context is needed to interpret the total result.
SHBG stands for sex hormone-binding globulin. Because total testosterone varies with SHBG, the total value may need to be assessed alongside it. Free testosterone is an additional measurement for relevant circumstances rather than a universal replacement for total testosterone.
The guideline describes different ways to assess free testosterone:
The EAU warns against direct free-testosterone estimates from available immunoassays. These should not be confused with the standardized total-testosterone immunoassays discussed above. The type of hormone measurement matters when discussing the test method.
If a result seems inconsistent with the clinical picture, a focused question is whether altered SHBG could be relevant and whether free-testosterone assessment would clarify the situation. The aim is to identify which measurement answers the clinical question, not to collect more numbers without a clear purpose.
A clinician considers the symptoms and confirmed measurements alongside the wider health history. The EAU recommends reviewing comorbidities and medications or substances that could affect testosterone production or action. It identifies acute illness as a reason to avoid measuring total testosterone.
The guideline identifies obesity and comorbidities such as diabetes as important contributors to late-onset hypogonadism. It also describes a gradual testosterone decline with aging in otherwise healthy men. Age is therefore part of the context rather than the only explanation worth considering.
When pathological total testosterone is found, the EAU recommends assessing LH and prolactin to help identify the underlying condition. LH and FSH can help distinguish types of hypogonadism. These markers address the possible source of a hormone pattern rather than merely adding another testosterone value.
Testostra's guide to considering the wider hormone pattern explains how those related results fit into the discussion.
Taken together, the clinical assessment asks whether the symptom pattern fits the biochemical findings and what might explain them. That is a more useful framework than judging each laboratory value as an isolated pass or fail.
A productive review connects the concern that prompted testing with the evidence needed to assess it. That includes documenting collection conditions and understanding the measurement method. It also means selecting related biomarkers because they answer a specific question.
The result is a better-informed conversation about the meaning of the report and the reasons for any further assessment. Diagnosis and treatment decisions remain with a qualified clinician.
How might future research on assay standardization and the role of free testosterone improve assessment when a man's symptoms and total testosterone results do not match?
Total testosterone, SHBG and free testosterone belong to the same clinical discussion, yet their roles are easy to confuse. Testostra's evidence-led articles explain how these biomarkers relate to hormone testing, giving readers clearer language for a clinician conversation without turning laboratory education into a personal diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra